| Metric | Value ($ M) | Q1 FY25 |
|---|---|---|
| Revenue | 0.02 | 0.0% |
| Total Income | 0.02 | 0.0% |
| Expenditure | 2.25 | 38.2% |
| PBT | — | |
| Net Profit | -3.02 | 18.6% |
| OPM | — | |
| NPM | — | |
| EPS | -0.69 | 1280.0% |
AIM ImmunoTech Announces Increase in Stockholder Equity and Note Extension
19 May 2026 · 19 May, 5:41 pm
Summary
AIM ImmunoTech Inc. announced a significant increase in stockholder equity and the extension of its promissory note maturity date to June 30, 2027. The company reported stockholder equity of approximately $2.1 million as of March 31, 2026, an increase of approximately $11.9 million since December 31, 2025. The company believes these developments will support its ability to manage capital resources and advance its pancreatic cancer development program. The outstanding balance of the note is approximately $1.68 million.
Key Highlights
- 1
AIM ImmunoTech reported a significant increase in stockholder equity.
- 2
Stockholder equity increased by approximately $11.9 million since December 31, 2025.
- 3
The company's stockholder equity was approximately $2.1 million as of March 31, 2026.
- 4
The maturity date of the promissory note has been extended to June 30, 2027.
- 5
The outstanding balance of the note is approximately $1.68 million following the amendment and associated extension fee.
- 6
The company believes the increase in stockholder equity and the note extension support its ability to manage capital resources.
Management Comments
Thomas Equels
“We appreciate the continued support and confidence demonstrated by Streeterville Capital through this extension. This amendment enhances our capital allocation flexibility at an important stage for the Company as we remain focused on executing our clinical and operational priorities. We believe the coming quarters present multiple potential catalysts that could create meaningful stockholder value and further expand our strategic optionality.”
Informational and educational content only. Not investment advice.